Updated December 2016

Meningococcal Vaccines for School-Age Children

July 12, 2017

See the table summary below for the different meningococcal vaccines required for students.

The Ontario Immunization of School Pupils Act (ISPA) was updated in 2014, to include vaccination against meningococcal disease. The following vaccines are required at particular ages for school attendance.

Meningococcal Vaccines for Students

Age Vaccine Type Trade Name
Routine childhood vaccination at 12 months of age. Parents need to provide proof of their child’s vaccination for school attendance, up to 11 years of age. Meningococcal-monovalent-C Menjugate®NeisVac®
Students in Grade 7, are offered the free quadrivalent vaccine at school. The quadrivalent vaccine is required for students’ ages 12 to 17 years. Meningococcal- quadrivalent ACYW-135
Menactra®
Menveo®
Niminrix®
High school students who did not receive the vaccine in Grade 7 or 8, still require the vaccine or can face suspension from school. Meningococcal- quadrivalent ACYW-135
Menactra®
Menveo®
Niminrix®

 

All vaccines required for school attendance are publicly funded

If high school students need the meningococcal vaccine, do not send them to the pharmacy to purchase the vaccine.

Action steps:

  • Order the quadrivalent vaccine directly through Toronto Public Health using the Menactra® vaccine order form.

or

  • Refer the student to tphbookings.ca for free vaccination at a Toronto Public Health clinic.

Order Vaccines

There are three types of meningococcal vaccines for high-risk groups. For clarification on eligibility, call 416-338-2030 to speak with our nurses.

Meningococcal Conjugated A, C, Y, W-135 (MEN-C-ACYW)

Brand Names: Menactra®, Menveo™, Nimenrix®

Routine eligibility: Students in Grade 7 through Toronto Public Health school clinics. Students who have not received the vaccine in Grade 7 remain eligible for one publicly funded dose.

High-risk eligibility for individuals from 9 months to 55 yrs with:

  • functional or anatomic asplena
  • complement, properdin, factor D deficiency or primary antibody deficiencies
  • pre/post Cochlear implant recipients
  • HIV
  • Acquired complement deficiency

New Schedule for high-risk clients: Age appropriate primary series followed by booster dose for all high-risk individuals.

Multicomponent Meningococcal B (4CMenB)

Brand Names: Bexsero®

Routine eligibility: Not publicly funded

High risk eligibility for individuals ages 2 months to 17 years with:

  • functional or anatomic asplenia
  • complement, properdin, factor D or primary antibody deficiencies
  • pre/post Cochlear implant recipients
  • acquired complement deficiencies (e.g., receiving eculizumab)
  • HIV

Schedule for high risk clients: Primary series are based on age.

Meningococcal Polysaccharide ACYW-135 (Men-P-ACYW)

Brand Names: Menomune®

Routine eligibility: Not publicly funded

High risk eligibility for individuals 56 and older with:

  • functional or anatomic asplena
  • complement, properdin, factor D deficiency or primary antibody deficiencies
  • pre/post Cochlear implant recipients

Schedule for high risk clients: one dose.  At least 5 years is required between doses of Men-C-ACYW and Men-P-ACYW for adults ≥55 years of age who have already received Men-C-ACYW